Share on StockTwits

Albany Molecular Research (NASDAQ:AMRI) CFO Michael M. Nolan unloaded 10,000 shares of Albany Molecular Research stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $19.76, for a total value of $197,600.00. Following the completion of the transaction, the chief financial officer now directly owns 76,093 shares in the company, valued at approximately $1,503,598. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

A number of analysts have recently weighed in on AMRI shares. Analysts at Zacks downgraded shares of Albany Molecular Research from an “outperform” rating to a “neutral” rating in a research note on Tuesday, August 12th. They now have a $23.70 price target on the stock. Separately, analysts at Morgan Stanley reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00. Finally, analysts at Sterne Agee reiterated an “underperform” rating on shares of Albany Molecular Research in a research note on Monday, July 7th. They now have a $15.00 price target on the stock, up previously from $13.00.

Albany Molecular Research (NASDAQ:AMRI) opened at 20.00 on Monday. Albany Molecular Research has a one year low of $9.71 and a one year high of $22.30. The stock’s 50-day moving average is $20.11 and its 200-day moving average is $17.06. The company has a market cap of $631.1 million and a price-to-earnings ratio of 40.44.

Albany Molecular Research (NASDAQ:AMRI) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.22 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.20 by $0.02. The company had revenue of $68.20 million for the quarter, compared to the consensus estimate of $65.64 million. On average, analysts predict that Albany Molecular Research will post $0.91 earnings per share for the current fiscal year.

Albany Molecular Research, Inc (NASDAQ:AMRI) is a contract research and manufacturing company.

Receive News & Ratings for Albany Molecular Research Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albany Molecular Research Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.